If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Pharmacokinetics === The oral bioavailability of setipiprant is 44% in rats and 55% in dogs, which suggests that it should be orally bioavailable in humans. The half-life of setipiprant in humans is about 11 hours. The maximum concentration in plasma (Cmax) is 6.04 and 6.44 mcg/mL for setipiprant tablets and capsules respectively, with an area under the curve of 31.88 and 31.50 mcg×hours/mL for setipiprant tablets and capsules respectively. Cmax was reached between 1.8–4 hours after oral administration. The tablet and capsule formulations are bioequivalent.
== Histology == The sulcular epithelium is a stratified squamous, non-keratinized epithelium that lines the gingival sulcus and extends from the coronal edge of the junctional epithelium to the free gingival margin.
Descended from Howard Fisher of the Fisher Brothers, owners of Fisher Body, from 1919 a part of General Motors, she has served as president of the General Motors Foundation and as executive director of global community relations and government relations at GM. She married Representative John Dingell in 1981. She had grown up as a Republican, but became a Democrat soon after marrying Dingell. Their marriage lasted 38 years until her husband's death on February 7, 2019, at the age of 92. Like her husband, she is a Catholic. She is a member of the Democratic National Committee from Michigan and chaired Vice President Al Gore's campaign in Michigan in 2000. In 2004, she also helped secure the Michigan Democratic primary and general election vote for John Kerry in Michigan. In November 2006, Dingell was elected to Wayne State University's board of governors. Dingell and Senator Carl Levin were proponents of moving up Michigan's presidential primary before February 5 in an attempt to garner greater political influence for Michigan during the 2008 Democratic primaries. This resulted in Michigan almost losing its delegates' votes in the Democratic National Convention. When Carl Levin announced his retirement from the U.S. Senate at the end of his term in 2015, Dingell indicated that she was interested in running for his seat. When former Michigan Governor Jennifer Granholm declined to run for the seat, a Politico writer declared Dingell to be one of the front-runners for the Democratic nomination, alongside Representative Gary Peters. She chose not to run, and Peters won the seat.
== Plantations == Blue gum is one of the most extensively planted eucalypts. Its rapid growth and adaptability to a range of conditions is responsible for its popularity. It is especially well-suited to countries with a Mediterranean-type climate, but also grows well in high altitudes in the tropics. It comprises 65% of all plantation hardwood in Australia with approximately 4,500 km2 (1,100,000 acres) planted. In about 1860 Francis Cook planted the tree on the Monserrate Palace, his property at Sintra in Portugal. By 1878 the tree "had spread from one end of Portugal to the other". E. globulus began to be planted as plantations in Los Lagos and Los Ríos regions of Chile in the 1990s. However at these latitudes around the 40th parallel south the tree is at the southern border of the climatic conditions where it can grow, hence good growth in this part of southern Chile requires good site selection such as sunny north-facing slopes. Some of these plantations grow on red clay soil.
Sources: en.wikipedia.org
=== Brand names === Tranexamic acid is marketed in the US and Australia in tablet form as Lysteda and in Australia, Sweden and Jordan it is marketed in an IV form and tablet form as Cyklokapron, in the UK and Sweden as Cyclo-F. In the UK it is also marketed as Femstrual, in Asia as Transcam, in Bangladesh as Intrax & Tracid, in India as Pause, in Pakistan as Transamin, in Indonesia as Kalnex, in South America as Espercil, in Japan as Nicolda, in France, Poland, Belgium, and Romania as Exacyl and in Egypt as Kapron. In the Philippines, its capsule form is marketed as Hemostan and in Israel as Hexakapron.
== Bioanalytical organisations == There are several national and international bioanalytical organisations active throughout the world. Often they are part of a bigger organisation, e.g. Bioanalytical Focus Group and Ligand Binding Assay Bioanalytical Focus Group, which are both within the American Association of Pharmaceutical Scientists (AAPS) and FABIAN, a working group of the Analytical Chemistry Section of the Royal Netherlands Chemical Society. The European Bioanalysis Forum (EBF), on the other hand, is independent of any larger society or association.
Play Australian rules football at any level; Enter the club premises or clubrooms on game day; Train under the direction of a club-devised program; or Return to their clubs' training sessions until two months before their bans expired. Because of these limitations, the bans also covered most forms of coaching. As such, two former players (Mark McVeigh and Henry Slattery) who were employed as non-playing coaches were suspended from their jobs, and players serving as playing coaches in country leagues were suspended from performing either function. The bans extended to any sport administered by a signatory to the WADA code, precluding active involvement in almost any organised sport during 2016. Players were not completely banned from involvement with the AFL, and were permitted to:
Sources: en.wikipedia.org
Additionally, operating these two-stage systems under thermophilic conditions (55 °C) has been validated as a robust strategy for full-scale applications, allowing for higher organic loading rates and optimized energy recovery compared to single-stage configurations.
Psilocybin is used recreationally, spiritually (as an entheogen), and medically. It is primarily taken orally, but other routes of administration, such as intravenous injection, are sometimes employed by licensed medical researchers using pharmaceutical-grade psilocybin powder designed for injection. Injection should never be attempted by unlicensed people.
Therefore, the HLB scale of sucrose esters as defined by suppliers up to now (March 2020) should be merely considered as an index ranking them from the most hydrophilic (high HLB) to the most lipophilic (low HLB). It is useful for comparing their properties within the sucrose ester family, but it should not be used as an experimental predictive tool for comparing their emulsifying properties to other kinds of surfactants, especially for high HLB index. The HLB scales, defined in the 1950s, have been built from experimental methods. It is notably the case of the Griffin's scale set above, that has been established experimentally by comparing the stability of emulsions involving different oils and stabilized by a large range of POE surfactants. From this large quantity of experimental data, an experimental HLB scale has been built up. Since a relationship between the surfactant structure and the results was observed, then a numerical equation has been worked out. The equation facilitated the determination of the HLB of new PEO surfactants without the need of new experiments. This calculation thus is strictly valid within the limit of the PEO surfactants family. Efforts to clarify the HLB of sucrose esters and related carbohydrate surfactants by experimental methods has been made in few works. Methods are based on the comparison of the stability of emulsions, on the "water number method" or on the "Phase Inversion Temperature" (PIT) method.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.